To further explore the biological phenotype of the VH11 and non-VH11 CLL subsets, we performed genome-wide gene expression profiling on primary IgH.TEμ CLL (tumor load >95%) expressing either a VH11 (n = 3) or a non-VH11 (n = 3) BCR. The gene discussed is BCR; the disease is neoplasm.